Werewolf Therapeutics (NASDAQ:HOWL) vs. Kymera Therapeutics (NASDAQ:KYMR) Head-To-Head Survey

Werewolf Therapeutics (NASDAQ:HOWL) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Volatility and Risk

Werewolf Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500.

Profitability

This table compares Werewolf Therapeutics and Kymera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Insider and Institutional Ownership

64.8% of Werewolf Therapeutics shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Werewolf Therapeutics and Kymera Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1	4	2	0	2.14
Kymera Therapeutics	1	0	21	1	2.96

Werewolf Therapeutics presently has a consensus price target of $3.75, suggesting a potential upside of 990.12%. Kymera Therapeutics has a consensus price target of $117.14, suggesting a potential upside of 30.30%. Given Werewolf Therapeutics’ higher possible upside, research analysts clearly believe Werewolf Therapeutics is more favorable than Kymera Therapeutics.

Earnings and Valuation

This table compares Werewolf Therapeutics and Kymera Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	N/A	N/A	-$60.82 million	($1.24)	-0.28
Kymera Therapeutics	$39.21 million	188.60	-$311.35 million	($3.57)	-25.18

Werewolf Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.